Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
The objective: to evaluate the efficacy and safety of delamanid in a short-course treatment regimen for patients with MDR/pre-XDR pulmonary tuberculosis in Arkhangelsk Region from 2019 to 2021.Subjects and Methods. 32 patients (4 with MDR TB and 28 with pre-XDR TB) started treatment with delamanid w...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2023-07-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1732 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The objective: to evaluate the efficacy and safety of delamanid in a short-course treatment regimen for patients with MDR/pre-XDR pulmonary tuberculosis in Arkhangelsk Region from 2019 to 2021.Subjects and Methods. 32 patients (4 with MDR TB and 28 with pre-XDR TB) started treatment with delamanid within the combination chemotherapy with new drugs, treatment lasted for 12 months. All patients with pre-XDR TB received delamanid, bedaquiline, linezolid, and clofazimine, then the chemotherapy regimen was compiled depending on the clinical situation.Results. Effective treatment was registered in 21/32 patients (65,6%). 4/32 (12,5%) patients interrupted the treatment. Treatment failure was registered in 2/32 (6,25%). During the study, 5 (15,6%) patients died, in none of them tuberculosis was the cause of death. 106 adverse events (AEs) were reported, they included electrolyte imbalance (18,9%), hepatotoxic (16,0%), nephrotoxic (10,4%) and cardiotoxic (10,4%) reactions. |
|---|---|
| ISSN: | 2075-1230 2542-1506 |